norfloxacin has been researched along with Liver Cirrhosis, Alcoholic in 15 studies
Norfloxacin: A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.
norfloxacin : A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.
Liver Cirrhosis, Alcoholic: FIBROSIS of the hepatic parenchyma due to chronic excess ALCOHOL DRINKING.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The extensive use of invasive procedures and of long-term norfloxacin prophylaxis in the management of cirrhotic patients may have influenced the epidemiology of bacterial infections in cirrhosis." | 7.71 | Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. ( Arroyo, V; Colmenero, J; Fernández, J; Gómez, J; Navasa, M; Rodés, J; Vila, J, 2002) |
| "We carried out quantitative culturing of stools from 31 hospitalized alcoholic patients with cirrhosis and ascites, before treatment with 400 mg of norfloxacin per day, weekly for the first month, and then every 2 weeks thereafter for 15 to 229 days (median, 54 days)." | 7.69 | Rapid emergence of quinolone resistance in cirrhotic patients treated with norfloxacin to prevent spontaneous bacterial peritonitis. ( Campillo, B; Dupeyron, C; Fouet, P; Leluan, G; Mangeney, N; Sedrati, L, 1994) |
| "Bacterial endotoxemia in patients with cirrhosis induces increased synthesis of nitric oxide that can be corrected with norfloxacin." | 5.08 | Effect of fluoroquinolone on the enhanced nitric oxide-induced peripheral vasodilation seen in cirrhosis. ( Chin-Dusting, JP; Dudley, FJ; Jennings, GL; Rasaratnam, B, 1997) |
| " Norfloxacin 400 mg per day had been introduced three months earlier as secondary prophylaxis for spontaneous bacterial peritonitis." | 3.72 | [Spontaneous infection of ascitic fluid due to Salmonella typhimurium in a cirrhotic patient undergoing selective intestinal decontamination with norfloxacin]. ( Colin, R; Di Fiore, F; Goria, O; Hervé, S; Lecleire, S; Lerebours, E; Savoye, G, 2003) |
| "The extensive use of invasive procedures and of long-term norfloxacin prophylaxis in the management of cirrhotic patients may have influenced the epidemiology of bacterial infections in cirrhosis." | 3.71 | Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. ( Arroyo, V; Colmenero, J; Fernández, J; Gómez, J; Navasa, M; Rodés, J; Vila, J, 2002) |
| "We carried out quantitative culturing of stools from 31 hospitalized alcoholic patients with cirrhosis and ascites, before treatment with 400 mg of norfloxacin per day, weekly for the first month, and then every 2 weeks thereafter for 15 to 229 days (median, 54 days)." | 3.69 | Rapid emergence of quinolone resistance in cirrhotic patients treated with norfloxacin to prevent spontaneous bacterial peritonitis. ( Campillo, B; Dupeyron, C; Fouet, P; Leluan, G; Mangeney, N; Sedrati, L, 1994) |
| "To determine the prevalence of bacterial infection in patients admitted to hospital with variceal bleeding in comparison with patients with liver cirrhosis admitted because of another reason." | 2.71 | Variceal bleeding in portal hypertension: bacterial infection and comparison of efficacy of intravenous and per-oral application of antibiotics--a randomized trial. ( Dastych, M; Díte, P; Husová, L; Juránková, J; Kroupa, R; Lata, J; Príbramská, V; Senkyrík, M, 2005) |
| "Oral pefloxacin would seem to be a convenient and useful treatment of spontaneous, gram-negative, bacterial peritonitis in cirrhosis." | 1.27 | Oral pharmacokinetics and ascitic fluid penetration of pefloxacin in cirrhosis. ( Beauchant, M; Becq-Giraudon, B; Bouquet, S; Breux, JP; Cardey, J; Fourtillan, JP; Silvain, C, 1987) |
| " It is proposed that the decreased plasma clearance of pefloxacin in patients with cirrhosis is a result of decreased hepatic metabolism of the drug, and that the dosage should probably be modified in these patients." | 1.27 | Pefloxacin kinetics in cirrhosis. ( Cunci, R; Danan, G; Erlinger, S; Montay, G, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (13.33) | 18.7374 |
| 1990's | 6 (40.00) | 18.2507 |
| 2000's | 7 (46.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lecleire, S | 1 |
| Di Fiore, F | 1 |
| Hervé, S | 1 |
| Goria, O | 1 |
| Savoye, G | 1 |
| Colin, R | 1 |
| Lerebours, E | 1 |
| Rasaratnam, B | 2 |
| Kaye, D | 1 |
| Jennings, G | 1 |
| Dudley, F | 1 |
| Chin-Dusting, J | 1 |
| Albillos, A | 1 |
| Hera Ad, Ade L | 1 |
| Reyes, E | 1 |
| Monserrat, J | 1 |
| Muñoz, L | 1 |
| Nieto, M | 1 |
| Prieto, A | 1 |
| Sanz, E | 1 |
| Alvarez-Mon, M | 1 |
| Lata, J | 1 |
| Juránková, J | 1 |
| Husová, L | 1 |
| Senkyrík, M | 1 |
| Díte, P | 1 |
| Dastych, M | 1 |
| Príbramská, V | 1 |
| Kroupa, R | 1 |
| Velayos Jiménez, B | 1 |
| Fernández Salazar, L | 1 |
| Aller Fuente, R | 1 |
| del Olmo Martínez, L | 1 |
| de la Calle Valverde, F | 1 |
| Arranz Santos, T | 1 |
| González Hernández, JM | 1 |
| Schölmerich, J | 1 |
| Gerbes, AL | 1 |
| Andus, T | 1 |
| Leser, HG | 1 |
| Dupeyron, C | 1 |
| Mangeney, N | 1 |
| Sedrati, L | 1 |
| Campillo, B | 1 |
| Fouet, P | 1 |
| Leluan, G | 1 |
| Wesenfelder, L | 1 |
| Eugène, C | 1 |
| Chin-Dusting, JP | 1 |
| Jennings, GL | 1 |
| Dudley, FJ | 1 |
| Barrio, J | 1 |
| Castiella, A | 1 |
| López, P | 1 |
| Indart, A | 1 |
| Arenas, JI | 1 |
| Romero-Gómez, M | 1 |
| Suárez García, E | 1 |
| Fernández, MC | 1 |
| Fernández, J | 1 |
| Navasa, M | 1 |
| Gómez, J | 1 |
| Colmenero, J | 1 |
| Vila, J | 1 |
| Arroyo, V | 1 |
| Rodés, J | 1 |
| Cardey, J | 1 |
| Silvain, C | 1 |
| Bouquet, S | 1 |
| Breux, JP | 1 |
| Becq-Giraudon, B | 1 |
| Fourtillan, JP | 1 |
| Beauchant, M | 1 |
| Danan, G | 1 |
| Montay, G | 1 |
| Cunci, R | 1 |
| Erlinger, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Hemodynamic Response of Rifaximin and Non-selective β-blocker Combination Therapy Versus Non-selective β-blocker Monotherapy in Cirrhotic Patients With Esophageal Varices[NCT01897051] | Phase 2/Phase 3 | 140 participants (Anticipated) | Interventional | 2013-07-31 | Recruiting | ||
| Comparison of 3 Days and 7 Days Intravenous Ceftriaxone Prophylaxis in Patients With Acute Variceal Bleeding[NCT00838864] | Phase 4 | 79 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| Patterns of Antibiotic Resistant Bacterial Infections in Liver Intensive Care Unit[NCT03855709] | 200 participants (Anticipated) | Observational | 2019-05-31 | Not yet recruiting | |||
| Comparison of Daily Norfloxacin Versus Weekly Ciprofloxacin for the Prevention of Spontaneous Bacterial Peritonitis in Cirrhotic Patients[NCT01542801] | Phase 4 | 124 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| Rifaximin Versus Norfloxacin in the Primary Prophylaxis of Spontaneous Bacterial Peritonitis[NCT04159870] | Phase 3 | 322 participants (Anticipated) | Interventional | 2019-11-05 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for norfloxacin and Liver Cirrhosis, Alcoholic
| Article | Year |
|---|---|
[Spontaneous bacterial peritonitis in liver cirrhosis with ascites].
Topics: Anti-Bacterial Agents; Ascites; Bacteria; Bacterial Infections; Blood; Endoscopy; Humans; Leukocyte | 1995 |
4 trials available for norfloxacin and Liver Cirrhosis, Alcoholic
| Article | Year |
|---|---|
The effect of selective intestinal decontamination on the hyperdynamic circulatory state in cirrhosis. A randomized trial.
Topics: Anti-Infective Agents; Bacterial Translocation; Cross-Over Studies; Double-Blind Method; Endotoxins; | 2003 |
Tumour necrosis factor-alpha expression by activated monocytes and altered T-cell homeostasis in ascitic alcoholic cirrhosis: amelioration with norfloxacin.
Topics: Acute-Phase Proteins; Anti-Infective Agents; Ascites; Carrier Proteins; Case-Control Studies; Entero | 2004 |
Variceal bleeding in portal hypertension: bacterial infection and comparison of efficacy of intravenous and per-oral application of antibiotics--a randomized trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Ampicillin; Anti-Bacterial Agents; Bacterial I | 2005 |
Effect of fluoroquinolone on the enhanced nitric oxide-induced peripheral vasodilation seen in cirrhosis.
Topics: Anti-Infective Agents; Cross-Over Studies; Double-Blind Method; Endotoxemia; Forearm; Humans; Liver | 1997 |
10 other studies available for norfloxacin and Liver Cirrhosis, Alcoholic
| Article | Year |
|---|---|
[Spontaneous infection of ascitic fluid due to Salmonella typhimurium in a cirrhotic patient undergoing selective intestinal decontamination with norfloxacin].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antibiotic Prophylaxis; Ascitic Fluid; Blood; Cefotaxi | 2003 |
Summaries for patients. Oral administration of an antibiotic (norfloxacin) may help treat the cardiac and circulatory complications of liver failure.
Topics: Anti-Infective Agents; Bacterial Translocation; Cross-Over Studies; Double-Blind Method; Endotoxins; | 2003 |
[Spontaneous bacterial peritonitis due to Gemella morbillorum in a patient under chronic treatment with norfloxacin].
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents; Ascites; Humans; Liver Cirrhosis, Alcoholic; Mal | 2008 |
Rapid emergence of quinolone resistance in cirrhotic patients treated with norfloxacin to prevent spontaneous bacterial peritonitis.
Topics: Ascites; Drug Resistance, Microbial; Enterobacteriaceae; Enterobacteriaceae Infections; Feces; Human | 1994 |
[Peritoneal tuberculosis masked by fluoroquinolones in a patient with liver cirrhosis].
Topics: Anti-Bacterial Agents; Ascites; Drug Therapy, Combination; Humans; Liver Cirrhosis, Alcoholic; Male; | 1993 |
[Spontaneous bacterial peritonitis caused by Streptococcus milleri in a cirrhotic patient with selective intestinal decontamination].
Topics: Aged; Anti-Infective Agents; Humans; Intestines; Liver Cirrhosis, Alcoholic; Male; Norfloxacin; Peri | 1998 |
Norfloxacin-induced acute cholestatic hepatitis in a patient with alcoholic liver cirrhosis.
Topics: Anti-Infective Agents; Antibiotic Prophylaxis; Chemical and Drug Induced Liver Injury; Cholestasis, | 1999 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Oral pharmacokinetics and ascitic fluid penetration of pefloxacin in cirrhosis.
Topics: Adult; Aged; Anti-Infective Agents; Ascitic Fluid; Diffusion; Female; Humans; Liver Cirrhosis, Alcoh | 1987 |
Pefloxacin kinetics in cirrhosis.
Topics: Adult; Aged; Biotransformation; Chromatography, High Pressure Liquid; Female; Half-Life; Humans; Inf | 1985 |